#USA #South San Francisco #Rigel Pharmaceuticals #TAVALISSE #VEPPANU

Rigel Pharmaceuticals Announces Q2 2026 Financial Results

Rigel Pharmaceuticals, based in South San Francisco, showcased remarkable financial performance for the second quarter of 2026, announcing total revenues of $78.7 million. The report, released on August 4, 2026, highlights an extraordinary increase in net product sales, reaching $67.0 million, alongside contract revenues from collaborations contributing $11.7 million.

Key Highlights

Financial Overview

The company's profitability is accentuated by a net income of $17.3 million, reflecting a healthy operational state despite the competitive landscape in biotechnology. Rigel's president and CEO, Raul Rodriguez, noted that this quarter marked a new record in net product sales, with the expansion into new product offerings anticipated to enhance their market position.

Product Development

One of the most significant developments this quarter is the in-licensing of VEPPANU™ (vepdegestrant), a groundbreaking proteolysis targeting chimera (PROTAC) that received FDA approval. This innovative drug targets estrogen receptor-positive breast cancer and is set to be commercially available in the U.S. by mid-August 2026, marking a strategic expansion into oncology.

Additionally, Rigel continues to drive the R289 clinical development program forward, particularly focusing on its Phase 1b study in lower-risk myelodysplastic syndromes (MDS). The company plans to complete patient enrollment for the crucial dose-expansion segment and select a recommended dose for Phase 2 trials by the end of 2026.

Business Updates

Through an exclusive global licensing agreement with Arvinas, Inc. and Pfizer, Rigel has positioned itself strongly within the oncology sector. The company engaged in a $70 million upfront payment for VEPPANU to kickstart launch activities promptly. This partnership illustrates Rigel’s tactical approach to leveraging collaborations to enhance its product portfolio.

Other notable transactions include Knight Therapeutics Inc. receiving regulatory approval to market TAVALISSE in Brazil for chronic immune thrombocytopenia and Kissei Pharmaceutical Co. applying for marketing approval in Japan for olutasidenib, which resulted in a significant milestone payment of $4 million to Rigel.

Clinical Developments and Future Outlook

Rigel's ongoing clinical trials have also produced promising data. The company's investigational compound, R289, is under scrutiny in clinical settings for its dual inhibition of interleukin receptor-associated kinases, which is critical for managing inflammatory conditions related to blood disorders. A paper published in Scientific Reports on R835, a metabolite of R289, affirms its efficacy through various preclinical studies, providing clinical insights into its potential benefits in managing inflammatory responses.

The company adjusted its 2026 financial outlook, forecasting total revenues to be between $285 million and $295 million. This optimistic projection signals confidence in its commercial strategies and product launches, particularly excluding the anticipated revenue from VEPPANU.

Closing Remarks

This positive momentum is bolstered by a strong leadership team, including the recent appointment of Dr. Alison L. Hannah as Chief Medical Officer, a move that is expected to drive further advancements in their clinical programs and strategic initiatives. As Rigel Pharmaceuticals gears up for an exciting second half of 2026, it remains focused on fulfilling unmet medical needs in the oncology and hematology fields, promising significant innovations ahead.

Rigel's next investor conference call is scheduled for today at 4:30 PM Eastern Time, where further insights into these results and future directions will be discussed. Rigel Pharmaceuticals continues to solidify its footprint in the biotechnology landscape, dedicated to developing therapies that enhance the quality of life for patients battling serious health conditions.